The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers ... the device directly to patients with asthma and COPD under a 510(k) over-the-counter ...
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
Nebulizers provide a cost-effective ... This article discusses special considerations in the selection of inhaler devices for elderly patients with COPD in the outpatient setting and provides ...
Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...
Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
News Medical on MSN13d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPDA study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...
The study offers promising solutions ... Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback